Company intelligence / Profile preview

Genialis

Boston, Massachusetts, United Statesgenialis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Genialis has developed AI-based biomarker models that predict patient response to targeted therapies, particularly for KRAS inhibitors. Their krasID biomarker has shown ability to predict response and clinical benefit to KRAS inhibitors across preclinical, clinical, and real-world settings[5].

Therapeutic areas: Oncology
Modalities: AI/ML-enabled biomarkers
Industry: Molecular Diagnostics

Partnerships

Pancreatic Cancer Action Network (PanCAN)pharmaceutical and diagnostics companies (specific names not provided)

Beyond the preview

Go deeper on Genialis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genialis.

Explore the full profile